Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 8/20 | 0.56 |
| ▸ | NPY4R | P50391 | 8/20 | 0.56 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.56 |
| ▸ | NPY1R | P25929 | 6/20 | 0.56 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.51 |
| ▸ | CALCR | P30988 | 3/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31196712 | 0.91 | NPY2R (0.53) | NPY2RNPY4RNPY5RNPY1RNTSR1 | |
| SCHEMBL30607331 | 0.88 | NPY2R (0.69) | NPY2RNPY4RNPY5RNPY1RNTSR1 | |
| SCHEMBL30930185 | 0.87 | NPY2R (0.54) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30400286 | 0.86 | NTSR1 (0.53) | NPY2RNPY4RNPY5RNPY1RNTSR1 | |
| SCHEMBL29455113 | 0.86 | NPY2R (0.65) | NPY2RNPY4RNPY5RNPY1RNTSR1 | |
| SCHEMBL31196711 | 0.86 | NPY2R (0.53) | NPY2RNPY4RNPY5RNPY1RNTSR1 | |
| SCHEMBL30432928 | 0.86 | NPY2R (0.56) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30997423 | 0.86 | NPY2R (0.54) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30930159 | 0.86 | NPY2R (0.54) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30930172 | 0.86 | NPY2R (0.52) | NPY2RNPY4RNPY5RNPY1RCALCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154113-A1 | Microcrystalline Diketopiperazine Compositions and Methods | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2025-05-15 | — | — | US | claimed |
| EP-3587404-B1 | MICROCRYSTALLINE DIKETOPIPERAZINE COMPOSITIONS, METHODS FOR PREPARATION AND USE THEREOF | MANNKIND CORP (US) | 2022-07-13 | — | — | EP | claimed |
| US-20220048868-A1 | Microcrystalline Diketopiperazine Compositions and Methods | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2022-02-17 | — | — | US | claimed |
| US-20260144877-A1 | HIGH CAPACITY DIKETOPIPERAZINE MICROPARTICLES AND METHODS | MANNKIND CORPORATION (US) | 2026-05-28 | — | — | US | disclosed |
| US-12508376-B2 | Dry powder inhaler | MANNKIND CORPORATION (US) | 2025-12-30 | — | — | US | disclosed |
| US-12447293-B2 | Dry powder inhaler and system for drug delivery | MANNKIND CORPORATION (US) | 2025-10-21 | — | — | US | disclosed |
| US-12433949-B2 | Sustained release delivery systems comprising traceless linkers | NOVARTIS AG (CH) | 2025-10-07 | — | — | US | disclosed |
| EP-3536368-B1 | DRY POWDER INHALER COMPRISING A SEROTONIN RECEPTOR AGONIST AND A DIKETOPIPERAZINE FOR TREATING MIGRAINES | MANNKIND CORP (US) | 2025-09-17 | — | — | EP | disclosed |
| US-12383552-B2 | Diketopiperazine microparticles with defined specific surface areas | MANNKIND CORPORATION (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250177481-A1 | SCO-spondin-derived polypeptides for enhancing synaptic transmission | AXOLTIS PHARMA (FR) | 2025-06-05 | — | — | US | disclosed |
| US-20250171497-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LIMITED (IE) | 2025-05-29 | — | — | US | disclosed |
| US-11345737-B1 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-05-31 | — | — | US | disclosed |
| US-11319346-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2022-05-03 | — | — | US | disclosed |
| US-20220119449-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LIMITED (IE) | 2022-04-21 | — | — | US | disclosed |
| US-11304992-B2 | Inhalable dry powder pharmaceutical composition | MANNKIND CORPORATION (US) | 2022-04-19 | — | — | US | disclosed |
| EP-3966321-A1 | ASX-SPECIFIC PROTEIN LIGASES AND USES THEREOF | Nanyang Technological University (SG) | 2022-03-16 | — | — | EP | disclosed |
| US-20220054499-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2022-02-24 | — | — | US | disclosed |
| US-20220047821-A1 | DRY POWDER INHALER AND SYSTEM FOR DRUG DELIVERY | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2022-02-17 | — | — | US | disclosed |
| US-20220048868-A1 | Microcrystalline Diketopiperazine Compositions and Methods | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2022-02-17 | — | — | US | disclosed |
| US-11248035-B1 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144877-A1 | HIGH CAPACITY DIKETOPIPERAZINE MICROPARTICLES AND METHODS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PKD2, SMCHD1 | NPY2R 57/4885NPY4R 64/4885NPY5R 20/4885 |
| US-12383552-B2 | Diketopiperazine microparticles with defined specific surface areas | DPP7, INSR, GPR119 | NPY2R 67/4885NPY4R 51/4885NPY5R 44/4885 |
| US-11304992-B2 | Inhalable dry powder pharmaceutical composition | GLP1R, IAPP, SLC5A2 | NPY2R 12/4885NPY4R 40/4885NPY5R 42/4885 |
| US-20220054499-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | MKI67, MYLK2, MYH2 | NPY2R 4339/4885NPY4R 4284/4885NPY5R 4471/4885 |
| US-20250171497-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | NPY2R 215/4885NPY4R 145/4885NPY5R 211/4885 |
| US-12433949-B2 | Sustained release delivery systems comprising traceless linkers | ABCB11, ABCB1, GHRHR | NPY2R 633/4885NPY4R 1081/4885NPY5R 1211/4885 |
| US-20220119449-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | NPY2R 215/4885NPY4R 145/4885NPY5R 211/4885 |
| US-20220048868-A1 | Microcrystalline Diketopiperazine Compositions and Methods | RRP15, DKK1, SPOP | NPY2R 180/4885NPY4R 179/4885NPY5R 62/4885 |
| US-20250154113-A1 | Microcrystalline Diketopiperazine Compositions and Methods | RRP15, DKK1, SPOP | NPY2R 180/4885NPY4R 179/4885NPY5R 62/4885 |
| US-12447293-B2 | Dry powder inhaler and system for drug delivery | CHRM3, CYP2D6, CHRM2 | NPY2R 899/4885NPY4R 1488/4885NPY5R 1002/4885 |
| US-12508376-B2 | Dry powder inhaler | CNR2, IL5, CNR1 | NPY2R 277/4885NPY4R 210/4885NPY5R 146/4885 |
| US-20220047821-A1 | DRY POWDER INHALER AND SYSTEM FOR DRUG DELIVERY | CHRM3, CYP2D6, CHRM2 | NPY2R 899/4885NPY4R 1488/4885NPY5R 1002/4885 |
| US-11319346-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | NPY2R 215/4885NPY4R 145/4885NPY5R 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.